**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 63655

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study**

Yang DH *et al*. HCC progression in HBV-related cirrhosis

Dan-Hong Yang, Wei-Ping Wang, Qiang Zhang, Hong-Ying Pan, Yi-Cheng Huang, Jia-Jie Zhang

**Dan-Hong Yang, Hong-Ying Pan, Yi-Cheng Huang, Jia-Jie Zhang,** Department of Infectious Diseases, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China

**Wei-Ping Wang, Qiang Zhang,** Postgraduate Department, Bengbu Medical College, Bengbu 233030, Anhui Province, China

**Author contributions:** Yang DH designed the research study; Yang DH and Wang WP analyzed the data and wrote the manuscript; Zhang Q, Pan HY, Huang YC and Zhang JJ collected the data; All authors have read and approved the final manuscript.

**Supported by** Zhejiang Provincial Natural Science Foundation, No. LY18H190002.

**Corresponding author: Dan-Hong Yang, PhD, Chief Doctor,** Department of Infectious Diseases, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou 310014, Zhejiang Province, China. ydh-11@163.com

**Received:** January 31, 2021

**Revised:** March 25, 2021

**Accepted:** April 2, 2021

**Published online:** May 7, 2021

**Abstract**

BACKGROUND

Antiviral therapy cannot completely block the progression of hepatitis B to hepatocellular carcinoma (HCC). Furthermore, there are few predictors of early HCC progression and limited strategies to prevent progression in patients with HBV-related cirrhosis who receive nucleos(t)ide analog (NA) therapy.

AIM

The study aim was to clarify risk factors and the diagnostic value of alpha-fetoprotein (AFP) for HCC progression in NA-treated hepatitis B virus (HBV)-related cirrhosis patients.

METHODS

In this retrospective cross-sectional study, we analyzed the clinical data of 266 patients with HBV-related cirrhosis who received NA treatment between February 2014 and April 2020 at Zhejiang Provincial People’s Hospital. The patients were divided into two groups, 145 who did not progress to HCC (No-HCC group), and 121 who progressed to HCC during NA treatment (HCC group). The logistic regression analysis was used to analyze the risk factors of HCC progression. The diagnostic value of AFP for HCC was evaluated by receiver operating characteristic (ROC) curve analysis.

RESULTS

Univariate analysis showed that age ≥ 60 years (*P* = 0.001), hepatitis B and alcoholic etiology (*P* = 0.007), smoking history (*P* < 0.001), family history of HBV-related HCC (*P* = 0.002), lamivudine resistance (*P* = 0.011), HBV DNA negative (*P* = 0.023), aspartate aminotransferase > 80 U/L (*P* = 0.002), gamma-glutamyl transpeptidase > 120 U/L (*P* = 0.001), alkaline phosphatase > 250 U/L (*P* = 0.001), fasting blood glucose (FBG) ≥ 6.16 (mmol/L) (*P* = 0.001) and Child-Pugh class C (*P* = 0.005) were correlated with HCC progression. In multivariate analysis, age ≥ 60 years [hazard ratio (HR) = 3.089, 95% confidence interval (CI): 1.437-6.631, *P* = 0.004], smoking history (HR = 4.001, 95%CI: 1.836-8.716, *P* < 0.01), family history of HBV-related HCC (HR = 6.763, 95%CI: 1.253-36.499, *P* < 0.05), lamivudine resistance (HR = 2.949, 95%CI: 1.207-7.208, *P* = 0.018), HBV DNA negative (HR = 0.026, 95%CI: 0.007-0.139, *P* < 0.01), FBG ≥ 6.16 mmol/L (HR = 7.219, 95%CI: 3.716-14.024, *P* < 0.01) were independent risk factors of HCC progression. ROC of AFP for diagnosis of HCC was 0.746 (95%CI: 0.674-0.818). A cutoff value of AFP of 9.00 ug/L had a sensitivity of 0.609, and specificity of 0.818 for diagnosing HCC.

CONCLUSION

Age ≥ 60 years, smoking history, family history of HCC, lamivudine resistance, HBV DNA negative, FBG ≥ 6.16 mmol/L were risk factors of HCC progression. Serum AFP had limited diagnostic value for HCC.

**Key Words:** Hepatitis B virus; Hepatocellular carcinoma; Cirrhosis; Risk factors; Nucleos(t)ide analogs; Progression

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analog therapy: A retrospective cross-sectional study. *World J Gastroenterol* 2021; 27(17): 2025-2038

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i17/2025.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i17.2025

**Core Tip:** This retrospective cross-sectional study analyzed risk factors of hepatocellular carcinoma (HCC) progression in hepatitis B virus-related cirrhosis patients receiving nucleoside acid analog therapy for at least 6 mo. We discuss the diagnostic value of serum alpha-fetoprotein level in these patients. The results of the present study increase our understanding of HCC pathogenesis and help to provide HCC prevention and control strategies.

**INTRODUCTION**

Liver cancer has the third-highest cancer mortality rate worldwide[1]. Hepatocellular carcinoma (HCC) is one of the most common subtypes of liver cancer and is the sixth most prevalent cancer type. In most countries, the HCC mortality rates have increased in recent decades[2]. HCC is the fourth most common malignant tumor type in China, accounting for over 55% of the total number of HCC cases[3]. Infection with the hepatitis B virus (HBV) greatly increases the incidence of HCC because HBV causes chronic hepatitis B (CHB), liver cirrhosis, and ultimately HCC[4,5]. The estimated risk of developing HCC was observed to be 25 to 37-fold higher in hepatitis B surface antigen (HBsAg) carriers compared with noninfected patients HBV infection is one of the most important contributors to the pathogenesis of HCC[6-8]. Over the past 30 years, antiviral drugs, especially nucleos(t)ide analogs (NAs), have been widely used in clinical practice and have substantial long-term effects on the inhibition of HBV replication, namely, delaying and reducing the occurrence and development of hepatitis B-related events. Many studies have shown that antiviral therapy can considerably decrease the incidence of HCC, even for patients in whom CHB has progressed to cirrhosis[9,10]. However, antiviral therapy does not completely block the progression of CHB to liver cancer[11,12]. In the current study, we analyzed the risk factors of HCC progression in patients with HBV-related cirrhosis who received NAs therapy for at least 6 mo. The diagnostic value of the serum alpha-fetoprotein (AFP) level was evaluated in those patients by receiver operating characteristic (ROC) curve analysis. The study results increase our understanding of HCC pathogenesis and help to provide HCC prevention and control strategies.

**MATERIALS AND METHODS**

***Patients and design***

This cross-sectional study retrospectively enrolled 266 patients with HBV-related cirrhosis who were treated with NA antiviral therapy at Zhejiang Provincial People’s Hospital between February 2014 and April 2020. The 266 patients were divided into two groups, 145with cirrhosis who did not progress to HCC during the observation period (No-HCC group), and 121 with cirrhosis who progressed to HCC (HCC group). The inclusion criteria were: (1) Age ≥ 18 years; (2) Treatment with lamivudine (LAM), adefovir (ADV), telbivudine, entecavir (ENT), or tenofovir (TDF) nucleoside or NAs for at least 6 mo; (3) Diagnosis of cirrhosis established by either histology (progressive fibrosis, nodule formation, and loss of hepatic architecture) or clinical data (symptoms and signs of cirrhosis, abnormal liver function, and ultrasonic identification). Demographic, clinical, laboratory, imaging, and pathology data were collected during the patient’s hospital stay. The severity of cirrhosis was classified by the Child-Pugh criteria. Patients with HBV-related cirrhosis were diagnosed in accord with the guidelines for the prevention and treatment of chronic hepatitis B formulated by the Hepatology Branch and the Infectious Diseases Branch of the Chinese Medical Association[13,14]; and (4) HCC and hepatitis diagnoses confirmed by clinical and serological characteristics, ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), hepatic arteriography with digital subtraction angiography (DSA) and pathological examination consistent with the hepatitis and primary liver cancer clinical diagnosis criteria[15,16]. The exclusion criteria were: (1) Hepatitis C virus, hepatitis D virus, or human immunodeficiency virus coinfection; (2) Autoimmune hepatitis and drug hepatitis; and (3) Hepatocarcinoma prior to antiviral treatment or within 6 mo after antiviral treatment. The study received no support from any pharmaceutical company and was approved by the Ethics Committee of the Zhejiang Provincial People’s Hospital (2020QT155), Hangzhou, Zhejiang Province, China.

***Data collection and study design***

The data collected from the electronic medical record system were age, sex, history of drinking and smoking, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin (ALB), glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), total bilirubin, fasting blood glucose (FBG), AFP, prothrombin time (PT), presence of ascites, hepatic encephalopathy, Child-Pugh score and classification, and family history of HBV, hepatitis B, and HCC. Serological markers of hepatitis B, serum content of HBV DNA, and history of NA treatment were reported by the patients or their families. All patients in the cohort were followed-up for 3 years or until death.

Serum liver function was tested by routine automated techniques using an Olympus AU5400 automated analyzer (Olympus, Tokyo, Japan). HBsAg, hepatitis B e-antigen (HBeAg), and hepatitis B e-antibody were assessed at baseline by chemiluminescence immunoassay (Abbott ARCHITECT i2000 SR analyzer; Abbott Diagnostics, Chicago, IL, United States). The serum HBV DNA load was assessed by RT-PCR using a LightCycler PCR system (Roche LightCycler480 II fluorescence quantitative PCR) in strict accordance with the instructions provided with the reagent kit (Shenzheng PG Biotech Co. Ltd, China). The detection limit was approximately 100 viral genome IU/mL. Genotypic resistance to LAM and ADV were determined at baseline by direct sequencing of the PCR amplification products. The serum AFP tumor marker was assayed by electrochemiluminescence. The study protocol conformed to the 1975 Declaration of Helsinki ethical guidelines for clinical studies.

***Statistical analysis***

Descriptive data were expressed as means ± standard deviation or *n* (%). Continuous variables were compared using Student’s *t*-test. Skewness distribution data were reported as the median with the range and were analyzed using the Mann–Whitney *U* test. Categorical variables were analyzed using Fisher’s exact test or Pearson’s *χ*2 test. A logistic regression model was used to analyze single factors, and multivariate analysis with stepwise regression was used to identify statistically significant variables in the single-factor analysis. The diagnostic performance of the serum AFP level was evaluated using ROC curves. The cutoff value, which was the maximum area under the ROC curve (AUROC), and accuracy were calculated with 95% confidence intervals (CIs). A *P*-value of less than 0.05 was determined to indicate statistical significance. The SPSS statistical package (version 22.0; SPSS, Chicago, IL, United States) was used for the statistical analysis.

**RESULTS**

***Clinical characteristics of HBV-related cirrhosis patients receiving NA therapy***

The clinical features of the No-HCC and the HCC group were compared. There were no significant differences between the two groups in the sex ratio, duration of NA therapy, HBsAg level, HBeAg positivity, jaundice index, Child-Pugh class B ratio, and PT level (*P* > 0.05). The HCC group included significantly more patients older than 60 years of age and patients with increased levels of ALT, AST, GGT, ALP, and FBG, and decreased levels of ALB than the No-HCC group. The HCC group also contained more patients with mixed etiology (alcohol + HBV), history of smoking, family history of HBV-related HCC, LAM resistance, Child-Pugh class C status, and an AFP > 20 μg/L and fewer HBV DNA-negative and Child-Pugh class A patients than the No-HCC group (Table 1).

***Risk factors for HCC progression in HBV-related cirrhosis patients receiving NA therapy***

We analyzed factors associated with HCC progression in HBV-related cirrhosis patients who received NA therapy. Univariate analysis found age ≥ 60 years (*P* = 0.002), HBV + alcohol mixed etiology (*P* = 0.007), smoking history (*P* < 0.001), family history of HBV-related HCC (*P* = 0.002), LAM resistance (*P* = 0.046), HBV DNA negativity (*P* = 0.023), AST > 80 U/L (*P* = 0.002), GGT > 120 U/L (*P* = 0.001), ALP > 250 U/L (*P* = 0.001), FBG ≥ 6.16 mmol/L (*P* = 0.001), and Child-Pugh class C (*P* = 0.005) to be significantly related to HCC (Table 2). Multivariate analysis showed that age ≥ 60 years [hazard ratio (HR) = 3.089, 95%CI: 1.437-6.631, *P* = 0.004], smoking history (HR = 4.001 95%CI: 1.836-8.716, *P* < 0.01), family history of HBV-related HCC (HR = 6.763, 95%CI: 1.253-36.499, *P* < 0.05), LAM resistance (HR = 2.949, 95%CI: 1.207-7.208, *P* = 0.018), HBV DNA negative (HR = 0.026, 95%CI: 0.007-0.139, *P* < 0.01), and FBG ≥ 6.16 mmol/L (HR = 7.219, 95%CI: 3.716-14.024, *P* < 0.01) independently predicted HCC progression in patients with HBV-related cirrhosis who received NAs therapy (Table 3).

***Serum AFP levels in the No-HCC and HCC groups***

In the HCC group, there were 56 patients with serum AFP levels > 20 μg/L, but that was seen in only 17 patients in the No-HCC group (*P* < 0.001). In the HCC group, 65 patients had AFP levels < 20 μg/L. The AFP levels of 37 patients in the HCC group were > 400 μg/L, but only two patients in the No-HCC group levels > 400 μg/L (*P* < 0.001, Table 4). The 17 patients in the No-HCC group with AFP levels > 20 µg/L were followed for 1 year. Their AFP level was determined every month and showed a dynamic decline, returning to normal within 1 year. All patients underwent enhanced MRI of imaging of the liver. We believe that hepatitis B activity, rather than HCC, led to the AFP abnormality. The AFP level distributions in the two groups are shown in Figures 1 and 2.

***Serum AFP has limited ability to diagnose HBV-related HCC***

We investigated the value of using serum AFP to diagnose HCC in patients who had HBV-related cirrhosis and were receiving NAs therapy. The AUROC of serum AFP for the diagnosis of HCC was 0.746 (95%CI: 0.674-0.818). The sensitivity of serum AFP in diagnosing HCC in those patients was 0.609, and the specificity was 0.818. The positive predictive value of HCC was 22.51%, the negative predictive value of HCC was 46.07%, the cutoff was 9.00, and the Youden index was 0.427 (Figure 3).

**DISCUSSION**

HBV infection remains a major risk factor for the development of cirrhosis and HCC[17]. Patients with chronic HBV are at risk of developing liver-related complications, namely, cirrhosis and HCC. In China, 77% of cirrhosis cases and 84% of HCC cases are caused by HBV infection[18]. Antiviral therapy can reduce but not eliminate the risk of developing HCC[19-21]. The annual incidence of HCC ranges from 0.01% to 5.4% in patients with CHB who are treated with ENT or TDF[19,22]. NAs antiviral treatments can markedly inhibit viral replication and improve liver necrosis, inflammation, and fibrosis. However, NAs cannot eliminate covalently closed template DNA (cccDNA) produced during hepatitis B viral replication or clear the integrated HBV genome; therefore, NAs cannot completely block hepatitis B cirrhosis from developing into HCC[12,21]. The persistence of cccDNA and an integrated HBV genome is the basis for hepatitis B cirrhosis progressing to primary liver cancer[23,24]. In this study, we investigated the clinical characteristics of HCC progression in patients with HBV-related cirrhosis who received antiviral therapy with NAs.

Medical and healthcare progress, improved living standards, and decreased population fertility have led to population aging in China. Data from 22 tumor registration centers in China have shown that the average age of liver cancer onset increased from 58.80 to 62.35 years for men and from 64.02 to 68.99 years for women between 2000 and 2014[25]. Our study found that age ≥ 60 years was an independent risk factor for the progression of hepatitis B-related cirrhosis to HCC while receiving NAs antiviral therapy. An aging population and the burden caused by HCC mortality could be a future challenge for China. Previous studies have confirmed that poor lifestyle habits are related to a high incidence of liver cancer; in particular, a history of smoking and drinking increases the risk of HCC[26,27]. Tobacco smoke contains various carcinogens, 11 of which are classified as International Agency for Research on Cancer Group 1 human carcinogens. Epidemiologic evidence from a recent meta-analysis showed a positive association between current tobacco smoking and liver cancer risk (risk ratio: 1.55, 95%CI: 1.46-1.65), suggesting a causal role of smoking in liver cancer development[28]. Liu *et al*[29] found that tobacco smoking and HBV infection positively interact in the development of liver cancer. Our results revealed smoking to be an independent risk factor of HCC progression (95%CI: 1.836-8.716, *P* < 0.01) even if the patients were receiving antiviral treatment. Studies have frequently reported that a family history of liver cancer increases HCC risk independent of hepatitis. The combination of a family history of liver cancer and hepatitis B serum markers is associated with a greater than 70-fold increase in HCC risk[30]. Super-additive and super-multiplicative interactions may exist between a family history of liver cancer and HBV infection that increase the risk of the development of liver cancer[31]. Our study found that a family history of HBV-related HCC is a risk factor of progression in cirrhotic patients receiving antiviral therapy (95%CI: 1.253-36.499, *P* < 0.05). Our results suggest that patients with HBV-related cirrhosis who smoke should quit smoking and cultivate a healthy lifestyle to reduce the risk of developing HCC[32,33]. Furthermore, close monitoring should be carried out if a patient’s first-degree relative develops HBV-related HCC during antiviral treatment.

LAM has been used as an antiviral treatment for hepatitis B for the past 20 years in China. Some Chinese patients with hepatitis B-related cirrhosis have previously undergone primary LAM monotherapy. Studies have shown that long-term LAM antiviral therapy can delay disease progression, reduce liver function decompensation, and reduce the incidence of HCC[34,35]. The inflammation seen in liver histology can improve in patients with hepatitis B-related cirrhosis when they are treated with LAM, but with a prolonged treatment time, the incidence of drug-resistant viral mutation increases[34,36]. The clinical benefit of LAM is limited by the emergence of resistant mutant strains and viral breakthrough. Although some LAM-resistant CHB patients have received ADV combination therapy or sequential ENT or TDF monotherapy, some of these patients did not experience a beneficial treatment effect and still had continuous replication of HBV in the liver[37,38]. In patients with LAM resistance, those with cirrhosis had a higher HCC risk than non-cirrhotic patients. Rescue treatment with ADV in patients who developed viral breakthrough did not appear to reduce the risk of HCC compared with untreated patients without remission[11]. In our study of patients treated with antiviral therapy for more than 6 mo, the number of HBV DNA-negative patients in the HCC group was lower than that in the No-HCC group. Many studies have found a correlation between serum HBV DNA levels and the occurrence of HCC in patients with hepatitis B. Kaneko *et al*[39] reported that detectable HBV DNA was significantly associated with a higher risk of HCC development compared with continuously undetectable HBV DNA. Chen *et al*[40] found that the incidence of HCC increased with serum HBV DNA level at study entry in a dose-response relationship ranging from 108/100,000 person-years for an HBV DNA level of < 300 copies/mL to 1152/100,000 person-years for an HBV DNA level of 1 million copies/mL or more. The corresponding cumulative incidence rates of HCC were 1.3% and 14.9%.

Even if the serum HBV DNA level in patients with hepatitis B-related cirrhosis is kept at a low level (< 2000 IU/mL), the risk of HCC is still high[41]. As shown in our study, HBV DNA negativity (HR = 0.026, 95%CI: 0.007-0.139, *P* < 0.01) independently predicted HCC progression in patients with HBV-related cirrhosis who received NAs therapy. Thus, to help avoid HCC progression, hepatitis B patients should continue to maintain an HBV DNA-negative status. Therefore, drugs with a high genetic barrier to resistance are suggested as first-line antiviral drugs for HBV therapy, and are recommended by current guidelines. Drugs such as ETV, TDF, and TDF alafenamide fumarate should be selected to generate a sustained antiviral treatment response and to reduce the occurrence of HBV resistance and the incidence of HCC[42,43].

As an important metabolic organ, the liver plays a key role in maintaining glucose homeostasis. Studies have found a positive relationship between liver cancer and diabetes mellitus[44,45]. Cell and animal experiments have shown that type 2 diabetes and male sex are associated with HCC development. Gao *et al*[46] demonstrated that heterozygous deletion of the *Ncoa5* gene caused spontaneous development of HCC exclusively in male mice, and NCOA5 deficiency increased susceptibility to both glucose intolerance and HCC. In a prospective cohort study, adjusted multivariable analysis showed that participants with 4.82 mmol/L ≤ FBG ≤ 5.49 mmol/L had a 47% increased risk of HCC, and those with an FBG > 5.49 mmol/L had a 69% increased risk[47]. In our study, the FBG level in the HCC group was higher than that in the No-HCC group (Table 1), and FBG ≥ 6.16 mmol/L was an independent risk factor for the HCC progression in patients with hepatitis B-related cirrhosis receiving NA antiviral treatment. Controlling blood sugar concentrations might be a way to decrease the risk of HCC in the Chinese population.

AFP is a glycoprotein that exists in a variety of different glycotypes. AFP has been used in the screening, diagnosis, efficacy evaluation, and prognosis evaluation of HCC. AFP elevation is commonly seen in active hepatitis, pregnancy, liver cancer, and embryonic tumors[48,49]. Previous studies reported that there was a significant correlation between serum AFP levels and the tumor size in liver cancer, and that the sensitivity and specificity of AFP depended on the selected serum level threshold[20,50]. Liu *et al*[51] found that approximately one-third of patients with HCC had normal serum AFP levels and that the level was related to the volume of liver cancer lesions, vascular invasion, and differentiation. In our study, we found 56 patients with a serum AFP > 20 µg/L, and 19 with serum AFP levels between 20 and 400 µg/L and with HCC confirmed by imaging and histopathological examination of liver masses. However, an AFP level of < 20 μg/L did not exclude the possibility of HCC. This study showed that 65 patients with a serum AFP of < 20 μg/L had space-occupying lesions that were confirmed as HCC by MRI enhancement, histopathology, and liver DSA examination. That indicates that more sensitive diagnostic markers of HCC must be developed. In addition, more sensitive serum tumor markers such as milk fat globule-EGF factor 8, osteopontin, miRNA classifier, glypican-3[52-54], and others should be actively investigated or combined to identify HCC at an early stage[55]. However, their clinical sensitivity and specificity must first be confirmed.

This study had some limitations. First, it was not prospective. The impact of antiviral treatment time and the amount of smoking and drinking on the development of HCC require confirmation in prospective studies with larger sample sizes. Second, longer follow-up and surveillance of HBV-related cirrhosis patients receiving NA therapy is necessary to observe whether they progress to HCC in their lifetime, even though the 145 cirrhotic patients with NA therapy did not progress to HCC during the observation period. Third, additional molecular markers should be assessed for their ability to provide an early diagnosis of HCC in patients with HBV-related cirrhosis. Some data indicate that the currently used potent NAs can reduce but not eliminate the risk of HCC. The inability to eliminate HCC risk might persist because of risk factors that are not amenable to change by antiviral therapy or because of events that may have taken place before treatment initiation.

**CONCLUSION**

In conclusion, age ≥ 60 years, a history of smoking, family history of HBV-related HCC, LAM resistance, HBV DNA negativity, and FBG ≥ 6.16 mmol/L were risk factors for HCC progression in patients with HBV-related cirrhosis who received NAs therapy. Patients with HBV-related cirrhosis should be treated with NA antiviral therapy that has a high genetic barrier to resistance[7] in order to improve the long-term response to antiviral therapy, to maintain an HBV DNA-negative status, and to prevent subsequent hepatitis activity. The early identification of HCC in patients with HBV-related cirrhosis remains difficult. Patients who receive antiviral therapy with NAs, especially those older than 60 years of age, should avoid smoking, control their blood sugar at a reasonable level, and undergo routine imaging examination of liver biochemistry and serum AFP evaluation. If space-occupying lesions are identified, the patient should undergo liver CT or MRI enhancement, or even liver DSA examination to identify HCC as promptly as possible, even if the AFP level is within the normal range.

**ARTICLE HIGHLIGHTS**

***Research background***

Antiviral therapy cannot completely block the progression of hepatitis B to hepatocellular carcinoma (HCC). Furthermore, there are few early predictors of HCC progression and early identification is difficult in patients with HBV-related cirrhosis who receive nucleos(t)ide analog (NA) therapy. The study is helpful to provide HCC prevention and control strategies by analyzing the risk factors of HCC progression and the diagnostic value of AFP for HCC in those people.

***Research motivation***

The study objective was to identify factors that affect the occurrence of HCC and how to identify early HCC in patients with hepatitis B virus (HBV)-related cirrhosis who receive NA therapy. The results can improve the understanding of the development of HCC in those patients so as to improve the early detection and prevention of HCC.

***Research objectives***

The study objectives were to clarify risk factors and the diagnostic value of alpha-fetoprotein (AFP) for HCC progression in patients with HBV-related cirrhosis treated with NAs and to provide new strategies for prevention and control of HCC in those patients.

***Research methods***

Logistic regression analysis was used to analyze the risk factors of HCC progression. The diagnostic value of AFP for HCC was evaluated by receiver operating characteristic curve analysis.

***Research results***

The study showed that age ≥ 60 years, smoking history, family history of HCC, lamivudine resistance, HBV DNA negativity, fasting blood sugar ≥ 6.16 mmol/L were independent risk factors of HCC progression. Serum AFP had limited diagnostic value for HCC. The results provide a meaningful strategy for early prediction and identification for HCC in those patients.

***Research conclusions***

A retrospective cross-sectional study was conducted to analyze risk factors of HCC progression in HBV-related cirrhosis patients receiving NA therapy. Metabolic effects of fasting blood sugar levels on the progress of HCC were seen during the receipt of NA therapy. The diagnostic value of the serum AFP level was evaluated in those patients.

***Research perspectives***

The study results will change the strategies used to prevent HCC in patients with HBV-related cirrhosis an receive NA therapy.

**REFERENCES**

1 **Sayiner M**, Golabi P, Younossi ZM. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. *Dig Dis Sci* 2019; **64**: 910-917 [PMID: 30835028 DOI: 10.1007/s10620-019-05537-2]

2 **Bertuccio P**, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E. Global trends and predictions in hepatocellular carcinoma mortality. *J Hepatol* 2017; **67**: 302-309 [PMID: 28336466 DOI: 10.1016/j.jhep.2017.03.011]

3 **Forner A**, Llovet IM, Bruix J. Hepatocellular carcinoma. *Lancet* 2012; **379**: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]

4 **McClune AC**, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. *Clin Liver Dis* 2010; **14**: 461-476 [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009]

5 **Ou DP**, Yang LY, Huang GW, Tao YM, Ding X, Chang ZG. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. *World J Gastroenterol* 2005; **11**: 2061-2066 [PMID: 15810069 DOI: 10.3748/wjg.v11.i14.2061]

6 **Chu CM**, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment. *Semin Liver Dis* 2006; **26**: 142-152 [PMID: 16673292 DOI: 10.1055/s-2006-939752]

7 **Chen QY**, Dong BQ, Yang JY, Wei SC, Fang KX, Wang XY, Fang ZL. [A prospective study of the relationship between serum hepatitis B virus DNA and the risk of primary liver cancer]. *Zhonghua Gan Zang Bing Za Zhi* 2009; **17**: 930-934 [PMID: 20038336]

8 **Chen YC**, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. *Hepatol Int* 2007; **1**: 267-273 [PMID: 19669348 DOI: 10.1007/s12072-007-5001-0]

9 **Lu T**, Seto WK, Zhu RX, Lai CL, Yuen MF. Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. *World J Gastroenterol* 2013; **19**: 8887-8894 [PMID: 24379612 DOI: 10.3748/wjg.v19.i47.8887]

10 **Wu CY**, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, Wu C, Wu JC. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. *Gastroenterology* 2014; **147**: 143-151.e5 [PMID: 24704525 DOI: 10.1053/j.gastro.2014.03.048]

11 **Papatheodoridis GV**, Lampertico P, Manolakopoulos S, Lok A. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. *J Hepatol* 2010; **53**: 348-356 [PMID: 20483498 DOI: 10.1016/j.jhep.2010.02.035]

12 **Papatheodoridis GV**, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK; HEPNET. Greece Cohort Study Group. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. *Gut* 2011; **60**: 1109-1116 [PMID: 21270118 DOI: 10.1136/gut.2010.221846]

13 **Hepatology Branch of Chinese Medical Association**. Infectious diseases branch of Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (2015 Edition). *Zhonghua Shiyan He linchuang Ganranbing Zazhi* 2015; **9**: 570-589 [DOI: 10.3877/cma.j.issn.1674-1358.2015.05.001]

14 **Hepatology Branch of Chinese Medical Association**. Infectious diseases branch of Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (2019 version). *Zhonghua Shiyan He linchuang Ganranbing Zazhi* 2019; **37**: 711-736 [DOI: 10.3760/cma.j.issn.1000-6680.2019.12.003]

15 **Ministry of Health of the People's Republic of China**. Standardization for diagnosis and treatment for hepatocellular carcinoma. *Zhonghua Zhongliu Linchunag* 2011; **16**: 929-946

16 **Health and Bureau of Medical Administration, National Health and Family Planning Commission of the people's Republic of China**. Standardization of diagnosis and treatment for hepatocellular carcinoma (2017 edition). *Zhonghua Waike Xiaohua Zazhi* 2017; **16**: 635-647 [DOI: 10.3760/cma.j.issn.1673-9752.2017.07.001]

17 **Chen JD**, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, Su J, Sun CA, Liaw YF, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. *Gastroenterology* 2010; **138**: 1747-1754 [PMID: 20114048 DOI: 10.1053/j.gastro.2010.01.042]

18 **Wang X**, Lin SX, Tao J, Wei XQ, Liu YT, Chen YM, Wu B. Study of liver cirrhosis over ten consecutive years in Southern China. *World J Gastroenterol* 2014; **20**: 13546-13555 [PMID: 25309085 DOI: 10.3748/wjg.v20.i37.13546]

19 **Arends P**, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; VIRGIL Surveillance Study Group. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. *Gut* 2015; **64**: 1289-1295 [PMID: 25011935 DOI: 10.1136/gutjnl-2014-307023]

20 **Vlachogiannakos J**, Papatheodoridis G. Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy. *World J Gastroenterol* 2013; **19**: 8822-8830 [PMID: 24379605 DOI: 10.3748/wjg.v19.i47.8822]

21 **Loomba R**, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ; REVEAL–HBV Study Group. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2013; **11**: 1636-45.e1-3 [PMID: 23669307 DOI: 10.1016/j.cgh.2013.04.043]

22 **Papatheodoridis GV**, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. *J Hepatol* 2015; **62**: 956-967 [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002]

23 **Yan H**, Yang Y, Zhang L, Tang G, Wang Y, Xue G, Zhou W, Sun S. Characterization of the genotype and integration patterns of hepatitis B virus in early- and late-onset hepatocellular carcinoma. *Hepatology* 2015; **61**: 1821-1831 [PMID: 25627239 DOI: 10.1002/hep.27722]

24 **Zeng HM**, Cao MM, Zheng RS, Zhang SC, Cai JQ, Qu CF, Bi XY, Zou XN, Chen WQ, He J. Trend analysis of mean age of diagnosis for liver cancer in cancer registry are as in China, 2000-2014. *Zhonghua Yufan Yixue Zazhi* 2018; **52**: 573-578

25 **Levrero M**, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. *J Hepatol* 2016; **64**: S84-S101 [PMID: 27084040 DOI: 10.1016/j.jhep.2016.02.021]

26 **Pascual S**, Herrera I, Irurzun J. New advances in hepatocellular carcinoma. *World J Hepatol* 2016; **8**: 421-438 [PMID: 27028578 DOI: 10.4254/wjh.v8.i9.421]

27 **Baecker A**, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. *Eur J Cancer Prev* 2018; **27**: 205-212 [PMID: 29489473 DOI: 10.1097/CEJ.0000000000000428]

28 **Abdel-Rahman O**, Helbling D, Schöb O, Eltobgy M, Mohamed H, Schmidt J, Giryes A, Mehrabi A, Iype S, John H, Tekbas A, Zidan A, Oweira H. Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: An updated systematic review of 81 epidemiological studies. *J Evid Based Med* 2017; **10**: 245-254 [PMID: 28891275 DOI: 10.1111/jebm.12270]

29 **Liu X**, Baecker A, Wu M, Zhou JY, Yang J, Han RQ, Wang PH, Jin ZY, Liu AM, Gu X, Zhang XF, Wang XS, Su M, Hu X, Sun Z, Li G, Mu L, He N, Li L, Zhao JK, Zhang ZF. Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population. *Int J Cancer* 2018; **142**: 1560-1567 [PMID: 29193051 DOI: 10.1002/ijc.31181]

30 **Turati F**, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, Franceschi S, Montella M, Polesel J, Zucchetto A, La Vecchia C, Negri E, Decarli A. Family history of liver cancer and hepatocellular carcinoma. *Hepatology* 2012; **55**: 1416-1425 [PMID: 22095619 DOI: 10.1002/hep.24794]

31 **Liu X**, Baecker A, Wu M, Zhou JY, Yang J, Han RQ, Wang PH, Jin ZY, Liu AM, Gu X, Zhang XF, Wang XS, Su M, Hu X, Sun Z, Li G, Fu A, Jung SY, Mu L, He N, Li L, Zhao JK, Zhang ZF. Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population. *Liver Int* 2019; **39**: 1490-1503 [PMID: 31228882 DOI: 10.1111/liv.14182]

32 **Singal AK**, Bataller R, Ahn J, Kamath PS, Shah VH. ACG Clinical Guideline: Alcoholic Liver Disease. *Am J Gastroenterol* 2018; **113**: 175-194 [PMID: 29336434 DOI: 10.1038/ajg.2017.469]

33 **Massarweh NN**, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. *Cancer Control* 2017; **24**: 1073274817729245 [PMID: 28975830 DOI: 10.1177/1073274817729245]

34 **Liaw YF**, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J; Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. *N Engl J Med* 2004; **351**: 1521-1531 [PMID: 15470215 DOI: 10.1056/NEJMoa033364]

35 **Su MH**, Lu AL, Li SH, Zhong SH, Wang BJ, Wu XL, Mo YY, Liang P, Liu ZH, Xie R, He LX, Fu WD, Jiang JN. Long-term lamivudine for chronic hepatitis B and cirrhosis: A real-life cohort study. *World J Gastroenterol* 2015; **21**: 13087-13094 [PMID: 26673249 DOI: 10.3748/wjg.v21.i46.13087]

36 **Yao GB**, Zhu M, Cui ZY, Wang BE, Yao JL, Zeng MD. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China. *J Dig Dis* 2009; **10**: 131-137 [PMID: 19426396 DOI: 10.1111/j.1751-2980.2009.00375.x]

37 **Chen CH**, Lin CL, Hu TH, Hung CH, Tseng PL, Wang JH, Chang JY, Lu SN, Chien RN, Lee CM. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. *J Hepatol* 2014; **60**: 1127-1134 [PMID: 24583247 DOI: 10.1016/j.jhep.2014.02.013]

38 **Wang Y**, Liu S, Chen YU, Zheng S, Zhou LI, Lu F, Duan Z. Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. *Exp Ther Med* 2016; **11**: 2293-2299 [PMID: 27313669 DOI: 10.3892/etm.2016.3230]

39 **Kaneko S**, Kurosaki M, Joko K, Marusawa H, Kondo M, Kojima Y, Uchida Y, Kimura H, Tsuji K, Yagisawa H, Kusakabe A, Kobashi H, Akahane T, Tamaki N, Kirino S, Abe T, Yoshida H, Matsushita T, Hasebe C, Izumi N. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. *Sci Rep* 2020; **10**: 13021 [PMID: 32747646 DOI: 10.1038/s41598-020-69522-w]

40 **Chen CJ**, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH; REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. *JAMA* 2006; **295**: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]

41 **Kim JH**, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. *Hepatology* 2017; **66**: 335-343 [PMID: 28012257 DOI: 10.1002/hep.28916]

42 **European Association for the Study of the Liver**. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370-398 [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021]

43 **Ghany MG**. Current treatment guidelines of chronic hepatitis B: The role of nucleos(t)ide analogues and peginterferon. *Best Pract Res Clin Gastroenterol* 2017; **31**: 299-309 [PMID: 28774412 DOI: 10.1016/j.bpg.2017.04.012]

44 **El-Serag HB**, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* 2004; **126**: 460-468 [PMID: 14762783 DOI: 10.1053/j.gastro.2003.10.065]

45 **Shang RZ**, Qu SB, Wang DS. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects. *World J Gastroenterol* 2016; **22**: 9933-9943 [PMID: 28018100 DOI: 10.3748/wjg.v22.i45.9933]

46 **Gao S**, Li A, Liu F, Chen F, Williams M, Zhang C, Kelley Z, Wu CL, Luo R, Xiao H. NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma. *Cancer Cell* 2013; **24**: 725-737 [PMID: 24332041 DOI: 10.1016/j.ccr.2013.11.005]

47 **Liu T**, Wang W, Cui H, Sun M, Wang Y, Liu X, Cao L, Liu H, Liu S. Elevated fasting serum glucose levels increase the risk of hepatocellular carcinoma: A prospective cohort study. *Medicine (Baltimore)* 2019; **98**: e16369 [PMID: 31348238 DOI: 10.1097/MD.0000000000016369]

48 **Meng W**, Bai B, Bai Z, Li Y, Yue P, Li X, Qiao L. The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma. *Discov Med* 2016; **21**: 489-494 [PMID: 27448785]

49 **Zhou L**, Liu C, Meng FD, Qu K, Tian F, Tai MH, Wei JC, Wang RT. Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. *Asian Pac J Cancer Prev* 2012; **13**: 483-486 [PMID: 22524811 DOI: 10.7314/apjcp.2012.13.2.483]

50 **Abbasi A**, Bhutto AR, Butt N, Munir SM. Corelation of serum alpha fetoprotein and tumor size in hepatocellular carcinoma. *J Pak Med Assoc* 2012; **62**: 33-36 [PMID: 22352098]

51 **Liu S**, Wang M, Zheng C, Zhong Q, Shi Y, Han X. Diagnostic value of serum glypican-3 alone and in combination with AFP as an aid in the diagnosis of liver cancer. *Clin Biochem* 2020; **79**: 54-60 [PMID: 32087138 DOI: 10.1016/j.clinbiochem.2020.02.009]

52 **Shimagaki T**, Yoshio S, Kawai H, Sakamoto Y, Doi H, Matsuda M, Mori T, Osawa Y, Fukai M, Yoshida T, Ma Y, Akita T, Tanaka J, Taketomi A, Hanayama R, Yoshizumi T, Mori M, Kanto T. Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. *Sci Rep* 2019; **9**: 15788 [PMID: 31673081 DOI: 10.1038/s41598-019-52356-6]

53 **Zhu M**, Zheng J, Wu F, Kang B, Liang J, Heskia F, Zhang X, Shan Y. OPN is a promising serological biomarker for hepatocellular carcinoma diagnosis. *J Med Virol* 2020 [PMID: 32043608 DOI: 10.1002/jmv.25704]

54 **Lin XJ**, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, Jia WH, Jie Y, Chen MS, Chen MX, Fang JH, Zeng C, Zhang Y, Guo RP, Wu Y, Lin G, Zheng L, Zhuang SM. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. *Lancet Oncol* 2015; **16**: 804-815 [PMID: 26088272 DOI: 10.1016/S1470-2045(15)00048-0]

55 **Forner A**, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018; **391**: 1301-1314 [PMID: 29307467 DOI: 10.1016/S0140-6736(18)30010-2]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of the Zhejiang Provincial People’s Hospital (2020QT155, Hangzhou, Zhejiang Province, China).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** January 31, 2021

**First decision:** March 14, 2021

**Article in press:** April 2, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Rodrigues AT **S-Editor:** Yan JP **L-Editor:** Filipodia **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 Distribution of alpha-fetoprotein levels in patients without hepatocellular carcinoma.** AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.



**Figure 2 Distribution of alpha-fetoprotein level in patients with hepatocellular carcinoma.** AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.



**Figure 3 Receiver operating characteristic curve analysis of alpha-fetoprotein to diagnose hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis receiving nucleos(t)ide analog therapy.** ROC: Receiver operating characteristic.

**Table 1 Comparison of the clinical characteristics of patients with and without hepatocellular carcinoma**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **no-HCC group (*n* = 145)** | **HCC group (*n* = 121)** | ***P-*value** |
| Age ≥ 60 yr, *n* (%) | 41 (28.3) | 64 (52.9) | < 0.001 |
| Male, *n* (%) | 99 (68.3) | 91 (75.2) | 0.133 |
| Etiology of liver cirrhosis, *n* (%) |  |  |  |
| HBV | 101 (60.7) | 76 (62.8) | 0.363 |
| HBV + alcohol | 31 (21.4) | 45 (37.2) | 0.006 |
| HBV + HEV | 1 (0.6) |  0 (0.0) | - |
| HBV + schistosome | 1 (0.6) | 0 (0.0) | - |
| Smoking history, *n* (%) | 21 (14.5) | 51 (42.1) | < 0.001 |
| Family history of HBV-related HCC, *n* (%) | 10 (6.9) | 23 (19.0) | 0.004 |
| Medication history |  |  |  |
| Duration of NA treatment, yr, median (P25, P75)] | 3.9 (2.1, 5.8) | 5.4 (2.3, 6.9) | 0.067 |
| LAM resistance, *n* (%) | 18 (12.4) | 27 (22.3) | 0.021 |
| HBsAg level, IU/L, median (P25, P75)] | 255.0 (56.0, 678.0) | 269.0 (67.0, 656.0) | 0.456 |
| HBeAg positive, *n* (%) | 37 (25.5) | 21 (17.4) | 0.136 |
| HBV DNA negative, *n* (%) | 67 (46.2) | 39 (32.2) | 0.033 |
| ALB, U/L | 36.29 ± 7.98 | 33.34 ± 6.62 | 0.002 |
| ALT, U/L, median (P25, P75) | 27.00 (18.00, 37.00) | 32.00 (21.27, 62.00) | 0.006 |
| AST, U/L, median (P25, P75) | 33.00 (23.00, 47.00) | 44.50 (31.65, 96.85) | < 0.001 |
| GGT, U/L, median (P25, P75) | 33.00 (20.00, 46.00) | 61.50 (32.75, 160.75) | < 0.001 |
| ALP, U/L, median (P25, P75)] | 99.00 (73.00, 126.00) | 134.50 (92.00, 198.85) | < 0.001 |
| TB, μmol/L, median (P25, P75) | 20.41 (13.81, 44.60) | 24.46 (16.60, 42.80) | 0.192 |
| FBS, mmol/L, median (P25, P75)] | 5.17 ± 0.68 | 6.99 ± 1.31 | 0.025 |
| Ascites, *n* (%) | 33 (20.0) | 43 (34.7) | 0.022 |
| Child-Pugh class, *n* (%) |  |  |  |
| A | 81 (55.9) | 55 (45.5) | 0.001 |
| B | 38 (26.2) | 26 (21.5) | 0.561 |
| C | 26 (17.9) | 40 (33.1) | 0.002 |
| AFP ≥ 20 μg/L, *n* (%) | 14 (9.7) | 56 (46.3) | < 0.001 |
| PT s, median (P25, P75) | 13.25 (11.80, 14.20) | 13.51 (12.41, 15.02) | 0.475 |

 AFP: Alpha-fetoprotein; ALB: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; FBS: Fasting blood sugar; GGT: Glutamyl transpeptidase; HBeAb: Hepatitis B e-antibody; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; LAM: Lamivudine; PT: Prothrombin time; SD: Standard deviation; TB: Total bilirubin.

**Table 2 Univariate logistic regression analysis of hepatitis B-related cirrhosis progressing to hepatocellular carcinoma in patients treated with nucleos(t)ide analogs**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **No-HCC group (*n* = 145)** | **HCC group (*n* = 121)** | **Univariate adjusted HR (95%CI)** | ***P*-value** |
| Age, yr |  |  |  |  |
| ≥ 60  | 40 (27.6) | 65 (52.9) | 2.664 (1.606-4.418) | 0.001 |
| < 60 | 105 (72.4) |  56 (46.3) |  |  |
| HBV + alcohol |  |  |  |  |
| Yes | 31 (21.4) | 45 (37.2) | 2.384 (1.271-4.473) | 0.007 |
| No |  |  |  |  |
| Smoking history |  |  |  |  |
| Yes | 21 (14.5) | 51 (42.1) | 4.073 (2.281-7.273) | < 0.001 |
| No |  |  |  |  |
| Family history of HBV-related HCC |  |  |  |  |
| Yes | 10 (6.9) | 23 (19.0) | 3.546 (1.573-7.998) | 0.002 |
| No |  |  |  |  |
| LAM resistance |  |  |  |  |
| Yes | 18 (12.4) | 27 (22.3) | 2.284 (1.214-4.297) | 0.011 |
| No |  |  |  |  |
| HBV DNA negative |  |  |  |  |
| Yes | 67 (46.2) | 39 (32.2) | 0.559 (0.339-0.922) | 0.023 |
| No |  |  |  |  |
| ALB (g/L) |  |  |  |  |
| < 35 | 67(46.2) | 62(51.2) | 1.223 (0.754-1.984) | 0.414 |
| ≥ 35 | 78 (53.8) | 59 (48.8) |  |  |
| ALT (U/L) |  |  |  |  |
| 50-100 | 13 (9.0) | 15 (12.4) | 1.324 (0.612-2.866) | 0.476 |
| > 100 | 10 (7.0) | 14 (11.6) | 1.138(0.482-2.688) | 0.768 |
| AST (U/L) |  |  |  |  |
| 40-80 | 32 (22.1) | 24 (19.8) | 0.919 (−0.713-0.514) | 0.783 |
| > 80 | 16 (10.3) | 31 (29.8) | 2.899 (0.436-1.767) | 0.002 |
| GGT (U/L) |  |  |  |  |
| 60-120 | 15 (10.3) | 20 (16.5) | 1.853 (0.892-3.847) | 0.098 |
| > 120 | 8 (5.1) | 28 (23.1) | 5.663 (1.075-2.573) | 0.001 |
| ALP (U/L) |  |  |  |  |
| 125-250 | 36(24.8) | 45 (38.8) | 1.609 (−0.062-1.028) | 0.073 |
| > 250 |  6 (1.4) | 21 (17.4) | 4.865 (0.667-2.993) | 0.001 |
| FBG (mmol/L) |  |  |  |  |
| ≥ 6.16 | 19 (13.1) | 37 (30.6) | 3.3179 (0.587-1.902) | 0.001 |
| < 6.16 |  |  |  |  |
| Ascites class |  |  |  |  |
| Yes | 33 (22.8) | 43 (35.5) | 0.834 (−0.412-0.060) | 0.142 |
| No |  |  |  |  |
| Child-Pugh class |  |  |  |  |
| A | 81 (58.6) | 55 (37.9) | 0.658 (−0.938-0.064) | 0.091 |
| B | 38 (26.2) | 26 (21.5) | 0.671 (−0.981-0.112) | 0.165 |
| C | 26 (17.9) | 40 (33.1) | 2.260 (0.247-1.427) | 0.005 |

Data are *n* (%) or mean ± SD as shown. AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CI: Confidence interval; FBG: Fasting blood glucose; GGT: Glutamyl transpeptidase; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HR: Hazard ratio; LAM: Lamivudine. .

**Table 3 Multivariate analysis of factors associated with hepatitis B-related cirrhosis progression to hepatocellular carcinoma in nucleos(t)ide analog-treated patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Risk factor** | **β** | **SE** | **Wald** | ***P-*value** | **OR (95%CI)** |
| Age ≥ 60 yr | 1.127 | 0.390 | 8.347 | 0.004 | 3.089 (1.437-6.631) |
| Smoking history | 1.387 | 0.397 | 12.180 | < 0.01 | 4.001 (1.836-8.716) |
| Family history of HBV-related HCC | 1.911 | 0.860 | 4.938 | < 0.05 | 6.763 (1.253-36.499) |
| LAM resistance | 1.082 | 0.456 | 5.638 | 0.018 | 2.949 (1.207-7.208) |
| HBV DNA negative | -3.479 | 0.816 | 19.427 | < 0.01 | 0.026 (0.007-0.139) |
| FBG ≥ 6.16 mmol/L | 1.977 | 0.339 | 34.030 | < 0.01 | 7.219 (3.716-14.024) |

CI: Confidence interval; FBG: Fasting blood glucose; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; LAM: Lamivudine OR: Odds ratio;; SE: Standard error.

**Table 4 Comparison of the alpha-fetoprotein level distributions in patients with and without hepatocellular carcinoma, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **AFP (μg/L)** | **No-HCC group (*n* = 145)** | **HCC group (*n* = 121)** | ***P-*value** |
| < 20 | 128 (88.27) | 65 (53.72) | < 0.001 |
| 20-100 | 12 (8.27) | 14 (11.57) | 0.51 |
| 100-200 | 1 (0.69) | 2 (2.17) | 0.231 |
| 200-400 | 2 (1.38) | 3 (2.48) | 1 |
| ≥ 400 | 2 (1.38) | 37 (30.58) | < 0.001 |

AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**